Chronic and acute conditions of the eye represent a significant health care challenge worldwide. The National Academy of Sciences recently declared eye health a public health emergency, and announced a goal of the elimination of correctable vision impairment by 2030. Chronic conditions of the eye, including glaucoma and dry eye are difficult to consistently treat, due to the prevalent use of eye drops requiring daily application, or even multiple medications. Patient compliance is a common problem, with estimates indicating between 30 to 50% of patients failing to apply their medications properly.
Acute conditions, including corneal lacerations, lye burns, and severe ulcers have limited therapeutic options. PolyCol’s collagen binding and healing capabilities, along with linked therapeutics appropriate to the specific condition, provide a superior potential option for these conditions.
Dry Eye Disease
Description Of Condition: Dry Eye Syndrome (DES) symptoms are burning, stinging, tiredness, light sensitivity, and blurred vision. DES is a disorder of the tear film and ocular surface.
Current Standard Of Care: Therapies replace eye lubrication with artificial tear-like material, or use anti-inflammatory drugs in an attempt to halt the inflammatory cycle that is one of the underlying causes of DES. A key drawback of current treatments is that the anti-inflammatory drugs act very slowly, and do nothing to immediately address the painful symptoms and damage to the ocular surface. Severe days are painful and potentially disabling for patients.
Our Solution: ST-100, in drop formulation, provides rapid healing of exposed sub-epithelial tissues, which creates the necessary environment for epithelial recovery, while also arresting inflammatory responses. ST-100 is broadly applicable to Dry Eye Disease patients and agnostic to underlying causes or stages of the disease.
Corneal Ulcers and Corneal Melting
Description Of Condition: Corneal ulcers and melting result from systemic disease conditions that manifest themselves in the eye, or from eye trauma with secondary infection. The eye surface is disrupted, and the condition can result in scarring, and eventual visual loss.
Current Standard Of Care: Topical drops are used over very short intervals (hourly), and multiple drops are used based on the underlying cause: antiviral, antifungal, and antibiotic, plus anti-inflammatory. Medications do not have a long residence time in the eye due to tear action.
Our Solution: PolyCol drops attach to damaged collagen present in the eye ulcer area, accelerating healing of the damaged collagen there, maximizing residence time of the linked therapeutic (various, based on etiology), enhancing their benefit. Frequency and dosage may be reduced, improving outcomes.
Description Of Condition: Painless, vision threatening condition that affects 3,000,000 patients in the U.S. Glaucoma kills optic nerve fibers that conduct vision through increased internal ocular pressure.
Current Standard Of Care: First level of care are drops, often multiple medications, applied one to four times daily. Patient compliance with drops is very poor, estimated at less than 50% in many studies. Because the treatment is preventative, and the condition has no active symptoms, motivation to self-administer is low.
Our Solution: Subconjunctival placement of the ST-101 insert, based on the TheraCol platform technology, provides an eight month steady delivery of prostaglandin analogue therapeutic, eliminating the need for patient administered drops.
Posterior Segment Inflammatory Conditions
Description Of Condition: Vitritis, Retinitis and Uveitis, inflammatory conditions of the posterior segment of the eye, can be caused by infections, autoimmune disorders, or genetic anomalies. Symptoms include pain, blurred vision, light sensitivity, and potentially loss of vision.
Current Standard Of Care: Parenteral or intraocular steroids are typically used to treat these conditions.
Our Solution: A TheraCol insert, in an extraocular placement, provides sustained transscleral delivery of corticosteroids or other therapeutics over a several month period, significantly reducing the risk of infection and the need for intraocular injections.
Wet Age Related Macular Degeneration
Description Of Condition: Wet Age Related Macular Degeneration is caused by abnormal blood vessels that leak blood or fluid into the macula, part of the retina responsible for central vision.
Current Standard Of Care: Current therapies include anti-VEGF medication delivered via an intraocular injection.
Our Solution: A TheraCol insert, in an extraocular placement, provides sustained release of anti-VEGF medication over a several month period, significantly reducing the need for intraocular injections and reducing the risk of infection.